Status message

The primary objective of this study is to determine the tolerability and optimal dose of cannabidiol (CBD) as an adjunct treatment in children and young adults with Sturge-Weber syndrome and drug resistant epilepsy. To begin to assess this we will do a small expanded access study with 5 subjects with medically refractory seizures and Sturge-Weber syndrome (SWS). We will assess safety and impact on their seizure frequency and severity (as measured by seizure length).